Vanguard Capital Management
DSGN icon

Vanguard Capital Management’s Design Therapeutics DSGN Stock Holding History

Vanguard Capital Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.7M Buy
1,571,022
+221,172
+16% +$2.76M ﹤0.01% 2374
2026
Q1 		$14.4M Buy
+1,349,850
New +$13.7M ﹤0.01% 2529

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

Vanguard Capital Management's DSGN Position: Q2 2026 in Review

Vanguard Capital Management increased its Design Therapeutics (DSGN) stake by 16% in Q2 2026, buying an estimated $2.76M and bringing the position to 1,571,022 shares worth $22.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2374.

Vanguard Capital Management first reported a position in DSGN in Q1 2026 and has held it in 2 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Vanguard Capital Management held 1,571,022 shares of Design Therapeutics worth $22.7M as of Q2 2026.
  • Vanguard Capital Management bought 221,172 Design Therapeutics shares in Q2 2026, an estimated $2.76M.
  • Design Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2374 holding.
  • Vanguard Capital Management first reported a position in Design Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.